Sarah A. Frech
Corporate Officer/Principal chez IOMAI CORPORATION
Profil
Dr. Sarah A.
Frech is Vice President-Clinical Development at Intercell USA, Inc. and Vice President-Clinical Research at Vtesse, Inc.
She received her undergraduate degree from Dartmouth College, a graduate degree from the Johns Hopkins Bloomberg School of Public Health, and a doctorate degree from Washington State University.
Postes actifs de Sarah A. Frech
| Sociétés | Poste | Début |
|---|---|---|
| IOMAI CORPORATION | Corporate Officer/Principal | - |
Anciens postes connus de Sarah A. Frech
| Sociétés | Poste | Fin |
|---|---|---|
Vtesse, Inc.
 Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Formation de Sarah A. Frech
| Dartmouth College | Undergraduate Degree |
| Washington State University | Doctorate Degree |
| Johns Hopkins Bloomberg School of Public Health | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Intercell USA, Inc.
 Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |
